Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lapix Therapeutics Inc. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is assigned to 1 distinct examiner working within 1 distinct art unit. The concentration of work suggests a highly focused prosecution effort rather than a broad, multi-front strategy across different USPTO divisions.
The busiest examiner for this portfolio is PIPIC, ALMA, who is responsible for 1 pending office action. Because this is the only active matter, this examiner handles the entirety of the company's current workload. Practitioners should note that the prosecution experience is centralized, meaning the outcomes of this specific interaction will define the current success rate for the portfolio.
With only 1 distinct art unit involved, the legal team can focus its technical arguments on the specific standards and precedents of that unit. The presence of 1 distinct examiner means that the relationship and communication style established with PIPIC, ALMA will be the primary factor in resolving the current active matter. This streamlined profile indicates a portfolio in a very specific stage of development.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIPIC, ALMA | 1 | 54.6% | +54.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | PIPIC, ALMA | 53d |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18579943 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | PIPIC, ALMA | 1617 | §103 | Non-Final OA | 53d | Pending | Jan 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial